3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
75
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
5
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Metastatic Castration-Resistant Prostate Cancer
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
Breast Neoplasms
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Solid Tumours
1
Salivary Gland Neoplasms
1
Prostatic Diseases
1
Prostate Cancer Metastatic Disease
1
Interventions
enzalutamide
8
Abiraterone Acetate
5
rucaparib
2
Prednisone
2
tildrakizumab
1
sabizabulin
1
pembrolizumab
1
fluzoparib
1
apatinib
1
abiraterone
1
Pluvicto
1
N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Castration Resistant Prostate Cancer
×
abiraterone
×
Clear all
NCT04179396
2023-06-29
RAMP
pharmaand GmbH
Phase 1
Completed
8 enrolled
8 charts